Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis

Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis

Introduction Patients are often treated with high doses or combinations of antipsychotics, which may hamper recovery. Dose-reduction (DR) or discontinuation of antipsychotic medication in chronic patients carries the risk of psychotic relapse. Objectives To identify risk factors of psychotic rel...

Full description

Bibliographic Details
Main Authors:	J. Bogers, G. Hambarian, J. Vermeulen, L. Dehaan
Format:	Article
Language:	English
Published:	Cambridge University Press 2021-04-01
Series:	European Psychiatry
Subjects:	dose reduction Relapse Risk factors meta-analysis
Online Access:	https://www.cambridge.org/core/product/identifier/S0924933821014267/type/journal_article

Similar Items

Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia– a case series
by: Sofie Norlin Mølgaard, et al.
Published: (2024-03-01)

Time-dependent effect of antipsychotic discontinuation and dose reduction on social functioning and subjective quality of life–a multilevel meta-analysisResearch in context
by: Björn Schlier, et al.
Published: (2023-11-01)

Cognitive Effects of Reducing First-Generation Antipsychotic Dose Compared to Switching to Ziprasidone in Long-Stay Patients with Schizophrenia
by: Jan P. A. M. Bogers, et al.
Published: (2024-04-01)

Does slow and steady win the race? Rates of antipsychotic discontinuation, antipsychotic dose, and risk of psychotic relapse
by: McCutcheon, RA, et al.
Published: (2023)

Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta‐analysis of observational studies
by: Tiffany Cristarella, et al.
Published: (2022-02-01)

Hypokalemia : what correlation with psychotic relapse ?
by: B. Abassi, et al.
Published: (2022-06-01)

Polypharmacy and relapse of schizophrenia: are they related?
by: R. Softic, et al.
Published: (2022-06-01)

Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy
by: David Buchser, et al.
Published: (2016-12-01)

An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders
by: Nadia E. Crellin, et al.
Published: (2022-03-01)

Benzodiazepines Reduce Relapse and Recurrence Rates in Patients with Psychotic Depression
by: Hiroki Shiwaku, et al.
Published: (2020-06-01)

Factors influencing relapse in patients with schizophrenia
by: P Nabeel, et al.
Published: (2023-01-01)

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia
by: Stanley N. Caroff, et al.
Published: (2018-09-01)

Dose reduction of biologics in patients with plaque psoriasis: a review
by: C. A. M. van Riel, et al.
Published: (2024-03-01)

Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice
by: S. Atalay, et al.
Published: (2022-04-01)

Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital
by: Ihechiluru G. Anozie, et al.
Published: (2022-04-01)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
by: L.S. van der Schoot, et al.
Published: (2023-12-01)

Predicting smoking cessation, reduction and relapse six months after using the Stop-Tabac app for smartphones: a machine learning analysis
by: Jean-François Etter, et al.
Published: (2023-06-01)

Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations
by: Orietta Zaniolo, et al.
Published: (2019-02-01)

Prescribing pattern of antipsychotics for patients with schizophrenia using the total daily dose online tool
by: Jawza F. Alsabhan, et al.
Published: (2023-12-01)

Dose Reduction Strategies for Pregnant Women in Emergency Settings
by: Carmine Picone, et al.
Published: (2023-02-01)

Assessment of Relapse in Patients with Schizophrenia during COVID-19 pandemic
by: E. Abdelfattah, et al.
Published: (2022-06-01)

Differences in Temporal Relapse Characteristics Between Affective and Non-affective Psychotic Disorders: Longitudinal Analysis
by: Sarah A. Immanuel, et al.
Published: (2021-02-01)

Risk factors for relapse of chronic pulmonary aspergillosis after discontinuation of antifungal therapy
by: Felix Bongomin, et al.
Published: (2020-04-01)

Acne Vulgaris Relapse in Sudanese Patients Treated with Oral Isotretinoin: Rate and Predictive Factors
by: Ibrahim S, et al.
Published: (2023-03-01)

Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis
by: Zina Sherzad Qadir, et al.
Published: (2023-11-01)

National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure
by: L. S. van der Schoot, et al.
Published: (2022-12-01)

Systematic Review and Dose-Response Meta-Analysis on the Relationship between Different Gluten Doses and Risk of Coeliac Disease Relapse
by: Mohammad Rostami-Nejad, et al.
Published: (2023-03-01)

Full dose, half dose, or discontinuation of etanercept biosimilar in early axial spondyloarthritis patients: a real-world study in China
by: Kun-Peng Li, et al.
Published: (2018-06-01)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
by: Mathews M, et al.
Published: (2020-06-01)

Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol
by: Eduardo Pondé de Sena, et al.
Published: (2003-10-01)

Productivity and deadweight losses due to relapses of schizophrenia in Japan
by: Nakamura Y, et al.
Published: (2017-05-01)

Schizophrenia relapse, patient considerations, and potential role of lurasidone
by: Citrome L
Published: (2016-08-01)

Therapeutic drug monitoring of LAI antipsychotics as a predictor of clinical relapse: a one-year follow-up
by: G. D’Anna, et al.
Published: (2022-06-01)

Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
by: Luo XW, et al.
Published: (2018-08-01)

Outcome of MS relapses in the era of disease-modifying therapy
by: Muriel Stoppe, et al.
Published: (2017-08-01)

Quality‐of‐life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia
by: Yilin Chen, et al.
Published: (2023-08-01)

Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment
by: Xia Zhang, et al.
Published: (2023-09-01)

The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia.
by: Spineli, L, et al.
Published: (2013)

The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia
by: Spineli, L, et al.
Published: (2013)

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Yue Sun, et al.
Published: (2020-11-01)